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complete versus target-vessel revascularization.
METHODS We analyzed retrospectively 114 patients, mean age 67  12
years, 69% male, hospitalized with NSTEMI between June and
December 2012 and followed-up 12 months. Inclusion criteria were
angiographic data for signiﬁcant atherosclerotic involvement of more
than one coronary artery and proceeding to percutaneous coronary
intervention (PCI). 71 patients (62%) underwent target-vessel revas-
cularization, the rest 43 (38%) – complete revascularization.
RESULTS Demographic and clinical characteristics did not differ
signiﬁcantly between groups except for smoking (more prevalent in
target-vessel revascularization group). Procedure success was 91%in
target-vessel revascularization group and 88% in patients with com-
plete revascularization. Rate of early in-hospital complications was
not signiﬁcantly different between the groups: mortality – 2 (2.7%)
versus 1 (2.3%), periprocedural myocardial infarction – 1(1.7%) versus
1(2.3%), in target-vessel and full revascularization groups,
respectively.
During one-year follow-up combined incidence of MACE (mortality,
myocardial infarction, revascularization) was signiﬁcantly reduced
after full revascularization (4 patients, 9.3%) compared to target-
vessel intervention (12 patients, 9%), p <0.01. the difference in MACE
was driven mainly from the signiﬁcant reduction in the rate of repeat
revascularization and mortality.
CONCLUSION NSTEMI patients have improved prognosis with com-
plete versus target vessel revascularization during one-year follow-
up, without increase in the rate of in-hospital complications.TCTAP A-015
Bleeding Events of STEMI Patients After PCI Is Associated with a Genetic
Risk Score Based on High-Risk Genetic Polymorphisms
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BACKGROUND Gene polymorphisms of ABCB1, CYP2C19, PON1 and
P2Y12 may inﬂuence pharmacodynamics and clinical events of clo-
pidogrel treatment. We assessed the hypothesis that a genetic risk
score based on identiﬁed high-risk single nucleotide polymorphisms
(SNPs) would be associated with bleedings in clopidogrel-treated
Chinese STEMI patients after percutaneous coronary intervention
(PCI).
A total of 510 consecutive patients with STEMI who received an
uneventful PCI and were exposed to clopidogrel treatment for 12
months, were enrolled in the single-center registry. There were 7
high-risk SNPs selected from ABCB1 (rs1045642, rs2235047), CYP2C19
(*17), PON1 (rs662, rs854560) and P2Y12 (rs6785930, rs6809699) genes,
which were detected by the ligase detection reaction. The primary
clinical safety endpoint was the incidence of major bleeding events.
Major bleeding was quantiﬁed according to bleeding academic
research consortium deﬁnition (BARC) criteria, including type 3 and 5
in the analysis. The follow-up period was 12months.
RESULTS Overall, 46 BARC3 bleeding events (9.0%) occurred, which
included 11 (2.2%) cases of BARC 3b bleedings and 35 (6.8%) cases of
BARC 3a bleedings. After adjustment for traditional clinical risk fac-
tors, multivariate logistic regression analysis identiﬁed SNPs signiﬁ-
cantly associated with bleedings were ABCB1 (rs1045642, rs2235047)
and P2Y12 (rs6785930, rs6809699). A genetic risk score was con-
structed by summing the number of risk alleles. As a continuous
variable, the risk score resulted in an OR of 1.326 per unit increase in
score (95%CI¼1.098-1.601, p¼0.003). The addition of this genetic risk
score signiﬁcantly increased AUC from 79.3% to 82.4% (p¼0.03), and
signiﬁcantly improved the predictive ability on bleeding risk by 20%
using the NRI approach (p¼0.01).
CONCLUSION This genetic score was signiﬁcantly associated with
bleedings after PCI in our study population.
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Sequential Therapy of Higher Doses of Atorvastatin Could Decrease
Soluble CD40L and Increase Coronary Blood Perfusion with Improvement
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Percutaneous Coronary Intervention
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BACKGROUND Studies indicate that soluble CD40 ligand (sCD40L) is
associated with disease progression and severity in acute coronarysyndrome (ACS), while it may provide a mechanistic link between
inﬂammation and myocardial reperfusion as well as cardiac function.
However, it is still controversial whether sequential therapy of
higher doses of atorvastatin could provide more beneﬁts in regu-
lating sCD40L, coronary blood perfusion and ventricular function
compared with a conventional dose in STEMI patients undergoing
primary PCI.
METHODS After screening, 136 STEMI patients met the inclusion
criteria and were included for analysis. All of them were divided into
three groups by using an electronic spreadsheet indicating the group
assignment by random numbers: Group A (n¼48) (received 80mg of
Atorvastatin before primary PCI, post-PCI follow-up Atorvastatin
40mg for 1 month, and Atorvastatin 20mg for 5 months); Group B
(n¼43) (received no pre-PCI loading dose of atorvastatin but did
receive Atorvastatin 40mg for 1 month and then Atorvastatin 20mg for
5 months); Group C (n¼45) (received only post-PCI Atorvastatin for
6months). TIMI ﬂow grade and Corrected TIMI Frame Count (CTFC)
after PCI would be recorded and compared among three groups. In
addition, the serum sCD40L and endothelial nitric oxide synthase
(eNOS) would be measured at admission and 1-day, 7-day, 1-month, 6-
month after PCI. Improvement of cardiac function would also be
evaluated during the follow-up.
RESULTS Patients among the three groups were well matched in de-
mographic and clinical characteristics (P>0.05). Patients in Group A
exhibited much better myocardial reperfusion indicated by CTFC
compared with Group B or Group C (no differences were observed in
TIMI ﬂow Grade 3 among three groups after PCI (P>0.05)). The levels
of sCD40L in Group A were signiﬁcantly lower than those in Group B
or Group C on 1-day and 7-day (P<0.05), but not in later sampling
points (P>0.05). Patients in Group A also gained higher levels of eNOS
and showed improvement in heart performance, with signiﬁcant in-
creases in their left ventricular ejection fraction (LVEF) (P<0.05).
Patients in Group B had relatively higher levels of eNOS as well as
signiﬁcant improvement in LVEF compared with Group C (P<0.05),
although no statistical differences were observed in sCD40L compar-
ison (P>0.05). No severe adverse reactions were observed during
study period.
CONCLUSION For STEMI patients, the sequential therapy of ator-
vastatin during primary PCI could signiﬁcantly lower serum sCD40L,
shorten CTFC and increase eNOS and LVEF. The sequential therapy of
atorvastatin treatment may reduce inﬂammatory response, improve
myocardial reperfusion and mend cardiac function with acute coro-
nary syndromes undergoing primary PCI. (ClinicalTrials.gov Identi-
ﬁer: NCT 01334671)
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BACKGROUND Recent studies of elderly patients demonstrate high
mortality from acute myocardial infarction (AMI) and increased risk
with advancing age. Although many oldest old AMI patients ( 85
years) have been treated by primary percutaneous coronary inter-
vention (pPCI) in the aging society, the prognostic importance of early
pPCI for these patients is unknown.
METHODS We evaluated consecutive 564 AMI patients (mean age
68.5 +/- 12.9, male 77%) from Mie ACS Registry in Japan from January
to December 2013. The pPCI was performed 86% patients. Patients
were divided into two groups according to the age; oldest old patients
( 85 years old: n¼62) and non-oldest old patients (< 85 years old:
n¼502). Primary end point was deﬁned as 30 days in-hospital
mortality.
RESULTS Percentage of chest pain at presentation of oldest old pa-
tients was tend to be lower than non-oldest patients (77 vs. 85%,
p¼0.13). However, there was no difference for prevalence of pPCI
between two groups, 30 days in-hospital mortality of oldest patients
was signiﬁcant higher than non-oldest patients (19.4 vs. 7%, p<0.01).
Even in the patients with pPCI, oldest patients showed poor 30 days
in-hospital mortality compared to the non-oldest patients (11.5 vs.
5.1%, p¼0.06). Only when analyzed patients with early pPCI (less
than 12 hours after onset), oldest patients showed similar favorable
prognosis to the non-oldest patients (Figure1A). However, oldest
patients with delayed pPCI(more than 12 hours) showed poor prog-
nosis compared to the non-oldest patients (Figure 1B). In
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pPCI were independent predictor for 30days in hospital mortality
(HR 2.7, 95%CI 1.6-4.5, p<0.01, and HR 4.5, 95%CI1.2-16.8, p¼0.03,
respectively).
CONCLUSION The oldest old patients showed various chief com-
plaints, which might lead to the delayed pPCI. However, we have to
provide the early pPCI for better prognosis, especially for the oldest
old AMI patients.
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BACKGROUND Early reperfusion in the setting of an ST-elevation
myocardial infarction is utmost importance. However, to provide
optimal care to patients with ST-segment elevated myocardial infarc-
tion (STEMI) is challenging. If a patient suffers from chest pain and calls
the emergency number, initiation of a cascade of actions leads to a
diagnosis, start of treatment and reperfusion of the infarcted myocar-
dium. Previous studies have shown that reporting or transmitting
prehospital ECG to the emergency department is an important part of
treatment for patients with STEMI. Themain beneﬁt of prehospital ECG
is its potential to reduce the overall treatment time to administration of
reperfusion therapy. Furthermore, prehospital ECG enhances early
arrival and triage to the emergency department, which is associated
with increased use of reperfusion interventions and shortened time to
treatment. However, it remained a challenging issue to set up pre-
hospital ECG in Taiwan because of involvement of complicated multi-
disciplinary team work. Therefore, we reported ﬁrst successful
experience of establishment of pre-hospital ECG in Kaohsiung city.
METHODS A multidisciplinary team among Kaohsiung Veterans
General hospital, ﬁre bureau and department of health, Kaohsiung
city government was organized since Sep, 2011. The key interventions
include to establish prehospital automatic interpretation ECG system
with immediate ECG transmission over mobile networks, to design a
ECG exam accessory device, to set up a incentive and auditing system,
to arrange EMT educational program, to set up a standard operative
procedure with transfer to appropriate hospital and Asian ﬁrst
ambulance prehospital mobile transmit ECG system. The consecutive
chest pain patients received ambulance ECG exam were enrolled from
Jan. 2011 to Feb. 2013 in 6 different ﬁre brigades at Kaohsiung city.
The patients were divided into three groups: pre-interventional group
from Jan to Dec 2011, Interventional group from Jan 2012 to Feb 2013
and post-interventional group from March 2013 to Feb 2014. The ECG
implementation rate is deﬁned as chest pain patients received
ambulance ECG exam divided by all patients with chest pain.
RESULTS We developed an ECG exam accessory device, which could
shorten ECG exam from 252 seconds to 30 seconds. The number ofmonthly chest pain patients received ambulance ECG exam increased
from zero patient in pre-interventional group, to 0.4 patients in
interventional group and to 14.2 patients in post-interventional group
(p<0.001).The ECG implementation rate increased from 0% in pre-
interventional group, to 0.6% in interventional group to 33.6% in
post-interventional group (p<0.001). Total 14 patients with STEMI
was detected in 175 chest pain patients received ambulance ECG
exam. In these STEMI patients, average door to balloon time was 53.5
minutes, average ischemia to balloon time was 111 minutes and in-
hospital mortality was 0%.
CONCLUSION The key factor to establish pre-hospital ECG system in
Kaohsiung city is cooperation of hospital, ﬁre bureau and department
of health of government. Furthermore, comprehensive EMT educa-
tion program and development of an ECG exam accessory device were
also critical to set up the pre-hospital ECG system.
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BACKGROUND Excimer laser coronary angioplasty (ELCA) has
been recently reimbursed from 2012 in Japan for percutaneous
coronary intervention (PCI). We evaluated the intermediate-term
clinical results of consecutive cases who underwent ELCA in our
hospital.
METHODS Between May 2012 and September 2014, consecutive 144
patients presented with acute coronary syndrome (ACS) and stable
coronary disease. ELCA was indicated by the operator after consid-
eration of the angiographic and intravascular ultrasound (IVUS) or
optical coherence tomography (OCT) ﬁndings.
RESULTS Of the 144 patients studied, Average age was 68.3 years old
and 82.3% was male. Lesion characteristics contained 63 ST-elevated
myocardial infarction (STEMI) (44%), 14 non-STEMI (9%), 19 unstable
Angina pectoris (uAP) (13%) and 48 stable angina pectoris (SAP) (34%).
Procedural success (device pass the lesion) was 97.8%. Treatable
coronary perforation occurred in 3 cases (2 cases were patients with
STEMI). 30 days mortality of STEMI patients was 5%.
CONCLUSION ELCA is feasible and safe device for the treatment of
patients with both patients with SAP and acute coronary syndrome.
Further investigations will be required with larger number of patients
to establish the effectiveness of ELCA.
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Intervention on Microvascular Perfusion Measured by Index of
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BACKGROUND Statin (3-hydroxy-3-methylglutaryl coenzyme A
reductase inhibitors), given before percutaneous coronary interven-
tion (PCI) was proven to reduce Major Cardiovascular Events (MACE)
in patient with stable angina as well as acute coronary syndromes
through it\’s pleiotropic effect. Nevertheless, the debate regarding
statin administration before primary PCI (PPCI) in STEMI patients is
still on the rise. The aim of this study is to establish therapeutic effect
of high dose atorvastatin (80 mg) and placebo before primary PCI on
microvascular perfusion in STEMI patient using index of microcircu-
latory resistance (IMR). IMR are speciﬁc and quantitative assessment
of coronary microvascular dysfunction, reliable on-site predictors of
short-term myocardial viability and left ventricle functional recovery
of patients undergoing primary PCI for STEMI.
METHODS This study is a double blind randomized controlled trial.
A high loading dose of atorvastatin (80 mg) or placebo was admin-
istered before PPCI. Samples were taken from the population of
STEMI patients which underwent PPCI and meet inclusion and
exclusion criteria. The primary end point of this study is IMR. After
successful primary percutaneous coronary intervention, IMR was
measured using a pressure-temperature sensor-tipped coronary
guidewire.
